Clinical study on the immediate of Shexiang Tongxin dropping pill on coronary slow blood flow and its long-term effect
- Conditions
- Coronary Slow Flow
- Registration Number
- ITMCTR2000003534
- Lead Sponsor
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Patients diagnosed as CSF;
2. TCM syndrome belongs to heart blood stasis obstruction;
3. Aged between 18~80 years;
4. Sign informed consent.
Note: the diagnosis of heart blood stasis syndrome refers to the diagnostic standard issued by the professional committee of promoting blood circulation and removing blood stasis of the Chinese Society of Integrated Chinese and Western Medicine in 2016.
(1) Tongue purple dark or have ecchymosis, stasis point;
(2) Lips purple or dark;
(3) Sublingual choroid varicose.
1. Patients with acute myocardial infarction or previous history of myocardial infarction;
2. Had a history of coronary intervention;
3. Patients with valvular heart disease, cardiomyopathy, coronary artery bridge, aortic dissection, acute pericarditis, acute pericarditis, cardiac insufficiency;
4. With uncontrolled grade 3 hypertension (systolic blood pressure >= 180 mmHg and/or diastolic blood pressure 110 mmHg), severe cardiopulmonary insufficiency, severe arrhythmia, serious essential diseases such as liver, kidney and hematopoietic system, or serious diseases affecting their survival (such as tumors) and mental patients;
5. Liver and kidney function Abnormal (ALTASTScr 1.5 times above the upper limit of normal reference range);
6. Allergic constitution, or to a variety of drugs food allergies, or known to test drugs (including their components) allergies;
7. Pregnant or lactating women with a pregnancy plan;
8. Abnormal thyroid function;
9. Patients who participated in other clinical trials within 1 month.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiac radionuclide score;ET-1;Lp-PLA2;Long-term efficacy;CD63;Immediate change of coronary blood flow;iNOs;hs-CRP;Blood stasis syndrome score;Coagulation function;CD62;IL-1;IL-6;NO;Corrected TIMI blood flow frame count;TNF-a;adropin;eNOs;
- Secondary Outcome Measures
Name Time Method rine routine;NT-proBNP;Blood routine;Color Doppler echocardiography;Stool routine;12-lead electrocardiogram;Liver and kidney function;Blood lipid;Heart damage (TnI\CK-MB\Myo);